SCHEMBL5331978

SCHEMBL5331978

Cc1ccc(S(=O)(=O)c2ccccc2C(N)=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
GAA P10253 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MMP2 P08253 5/20 0.48
MMP9 P14780 5/20 0.48
MMP8 P22894 5/20 0.48
MMP12 P39900 5/20 0.48
MMP13 P45452 5/20 0.48
MMP14 P50281 5/20 0.48
MMP16 P51512 5/20 0.48
MMP3 P08254 4/20 0.48
MMP1 P03956 2/20 0.48
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30901415 0.88 L3MBTL1 (0.44) HTR2AHTR2CGAAL3MBTL1MMP2
SCHEMBL364480 0.86 HTR6 (0.55) HTR2AHTR2CGAAMMP2MMP9
SCHEMBL13908249 0.85 MMP2 (0.53) GAAL3MBTL1MMP2MMP9MMP8
SCHEMBL27492085 0.85 HTR6 (0.54) HTR2AHTR2CMMP2MMP9MMP8
SCHEMBL31061277 0.83 HTR2A (0.51) HTR2AHTR2CMMP2MMP9MMP8
SCHEMBL22652933 0.83 GAA (0.48) GAAL3MBTL1MMP2MMP9MMP8
SCHEMBL8988719 0.83 CA1 (0.59) GAAL3MBTL1MMP2MMP9MMP8
Potassium SCHEMBL31176741 0.82 HTR2A (0.63) HTR2AHTR2CGAAMMP2MMP9
SCHEMBL9626817 0.81 RECQL (0.47) GAAL3MBTL1MMP2MMP9MMP8
SCHEMBL25302092 0.80 HTR2A (0.48) HTR2AHTR2CMMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569617-A1 WATER STABILIZED MEDICINAL AEROSOL FORMULATION RELATED APPLICATIONS Kos Life Sciences, Inc. (US) 2005-09-07 EP claimed
WO-2004022035-A1 WATER STABILIZED MEDICINAL AEROSOL FORMULATION RELATED APPLICATIONS KOS PHARMACEUTICALS, INC. (US) 2004-03-18 WO claimed
WO-2002007672-A2 A MEDICINAL AEROSOL FORMULATION AEROPHARM TECHNOLOGY, INC. (US) 2002-01-31 WO claimed
US-4307170-A ACID CATALYST - AZO COUPLERS PROMOTE DISCOLORATION AND BLOOM RESISTANCE JAMES RIVER GRAPHICS, INC. (US) 1981-12-22 US claimed
CN-116478181-B Catalytic synthesis method of chiral oxazoline compound 中国海洋大学 2024-05-17 CN disclosed
EP-4340828-A1 QUERCETIN-CONTAINING COMPOSITIONS FOR USE IN TREATING AMYOTROPHIC LATERAL SCLEROSIS Quercis Pharma AG (CH) 2024-03-27 EP disclosed
CN-116478181-A Catalytic synthesis method of chiral oxazoline compound 中国海洋大学 2023-07-25 CN disclosed
WO-2022243942-A1 QUERCETIN-CONTAINING COMPOSITIONS FOR USE IN TREATING AMYOTROPHIC LATERAL SCLEROSIS Quercis Pharma AG (CH) 2022-11-24 WO disclosed
WO-2022170075-A1 AUXINIC HERBICIDES AND METHODS OF USE THEREOF CORTEVA AGRISCIENCE LLC (US) 2022-08-11 WO disclosed
US-10669242-B2 Clostridium difficile toxin inhibitors Venenum Biodesign, LLC (US) 2020-06-02 US disclosed
US-20190194147-A1 Novel Clostridium Difficile Toxin Inhibitors Venenum Biodesign, LLC (US) 2019-06-27 US disclosed
EP-1745056-A4 ENANTIOSELECTIVE PHOSPHORAMIDITE COMPOUNDS AND CATALYSTS YALE UNIVERSITY CORP (US) 2007-10-31 EP disclosed
EP-1745056-A2 ENANTIOSELECTIVE PHOSPHORAMIDITE COMPOUNDS AND CATALYSTS Yale University Corporation (US) 2007-01-24 EP disclosed
WO-2005111050-A2 ENANTIOSELECTIVE PHOSPHORAMIDITE COMPOUNDS AND CATALYSTS YALE UNIVERSITY (US) 2005-11-24 WO disclosed
EP-1569617-A1 WATER STABILIZED MEDICINAL AEROSOL FORMULATION RELATED APPLICATIONS Kos Life Sciences, Inc. (US) 2005-09-07 EP disclosed
WO-2004022035-A1 WATER STABILIZED MEDICINAL AEROSOL FORMULATION RELATED APPLICATIONS KOS PHARMACEUTICALS, INC. (US) 2004-03-18 WO disclosed
WO-2002015883-A1 A METHOD OF STABILIZING A DRY POWDER PHARMACEUTICAL FORMULATION AEROPHARM TECHNOLOGY INCORPORATED (US) 2002-02-28 WO disclosed
WO-2002007672-A2 A MEDICINAL AEROSOL FORMULATION AEROPHARM TECHNOLOGY, INC. (US) 2002-01-31 WO disclosed
US-4307170-A ACID CATALYST - AZO COUPLERS PROMOTE DISCOLORATION AND BLOOM RESISTANCE JAMES RIVER GRAPHICS, INC. (US) 1981-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194147-A1 Novel Clostridium Difficile Toxin Inhibitors GABRA5, GABRA1, GABRA4 HTR2A 1936/4885HTR2C 1617/4885GAA 1644/4885
US-10669242-B2 Clostridium difficile toxin inhibitors GABRA5, GABRA1, GABBR2 HTR2A 1420/4885HTR2C 1166/4885GAA 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.